LPGO.ST Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 bal. 2024 @ 18:15):

Stats
Dzisiejszy wolumen	614 831
Średni wolumen	538 035
Kapitalizacja rynkowa	45.45M
EPS	SEK0 ( 2024-02-22 )
Następna data zysków	( SEK0 ) 2024-05-24
Last Dividend	SEK0 ( N/A )
Next Dividend	SEK0 ( N/A )
P/E	-1.890
ATR14	SEK0.00900 (2.50%)

Wolumen Korelacja

Długi: -0.06 (neutral)

Krótki: -0.59 (weak negative)

Signal:(58.156) Neutral

Lipigon Pharmaceuticals Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Lipigon Pharmaceuticals Korelacja - Waluta/Towar

0.14
( neutral )

0.08
( neutral )

0.00
( neutral )

-0.09
( neutral )

Lipigon Pharmaceuticals Finanse

Annual	2023
Przychody:	SEK16.41M
Zysk brutto:	SEK-12.58M (-76.66 %)
EPS:	SEK-0.190

FY	2023
Przychody:	SEK16.41M
Zysk brutto:	SEK-12.58M (-76.66 %)
EPS:	SEK-0.190

FY	2022
Przychody:	SEK390 000
Zysk brutto:	SEK366 000 (93.85 %)
EPS:	SEK-2.12

FY	2021
Przychody:	SEK3.18M
Zysk brutto:	SEK0.00 (0.00 %)
EPS:	SEK-4.56

Financial Reports:

No articles found.

Lipigon Pharmaceuticals

Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease and familial chylomicronemia syndrome; a gene therapy project for the lipodystrophy, a rare disease of altered fat distribution in the body; therapeutics for dyslipidemia, a general lipid disorder; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia, cardiovascular disease, and other metabolic diseases. The company was founded in 2010 and is based in Umeå, Sweden.